Aschoff is an idiot: “He was caught impersonating a doctor in order to get confidential information a few years ago. Why respected publications such as Barrons and Forbes continue associate themselves with this medical impersonator is baffling to say the least.”
I disagree. The data is too strong. Cubist bought TSRX 3 months ago for over a billion dollars and the drug isn't approved yet. The competitive advantage is very cut and dry. Baxter will likely take them out soon.
I'm with you. The amount of garbage on this message board and on twitter about AMRN is redic. NO ONE on this board has a clue how this is actually going to shake out on Wed. What we do know for a fact is the mineral oil concern (which is valid), but inconclusive and that the document clearly confirms efficacy and safety at the 200 to 500 dose. Again, no one knows how this is going to shake out. It's a 50/50 gamble.
It was years before GSK bought Lovaza (formerly Omacor)...Joe's last fish oil company. once the brand is more established (which it's clearly trending upward based on IMS data) the deal will come....
TRSX was bought out BEFORE their product was FDA approved just a few months ago. The product is still not FDA approved.
the drug is not approved by the FDA (the trials have to happen first). it simply received orphan drug status on the molecule. i'm long on this, but orphan molecule can still not be approved overall by the FDA.